ATE516044T1 - Attenuierte rotavirus-vakzine zur oralen verabreichung - Google Patents

Attenuierte rotavirus-vakzine zur oralen verabreichung

Info

Publication number
ATE516044T1
ATE516044T1 AT06707035T AT06707035T ATE516044T1 AT E516044 T1 ATE516044 T1 AT E516044T1 AT 06707035 T AT06707035 T AT 06707035T AT 06707035 T AT06707035 T AT 06707035T AT E516044 T1 ATE516044 T1 AT E516044T1
Authority
AT
Austria
Prior art keywords
oral administration
rotavirus vaccine
attenuated rotavirus
attenuated
vaccine
Prior art date
Application number
AT06707035T
Other languages
English (en)
Inventor
Velde Vincent Vande
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34385675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE516044(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of ATE516044T1 publication Critical patent/ATE516044T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT06707035T 2005-02-17 2006-02-15 Attenuierte rotavirus-vakzine zur oralen verabreichung ATE516044T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0503337.8A GB0503337D0 (en) 2005-02-17 2005-02-17 Compositions
PCT/EP2006/001442 WO2006087205A1 (en) 2005-02-17 2006-02-15 Live attenuated rotavirus vaccine for oral administration

Publications (1)

Publication Number Publication Date
ATE516044T1 true ATE516044T1 (de) 2011-07-15

Family

ID=34385675

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06707035T ATE516044T1 (de) 2005-02-17 2006-02-15 Attenuierte rotavirus-vakzine zur oralen verabreichung

Country Status (32)

Country Link
US (2) US8192747B2 (de)
EP (2) EP1863526B1 (de)
JP (1) JP5118977B2 (de)
KR (1) KR101319846B1 (de)
CN (2) CN103357005A (de)
AP (1) AP2692A (de)
AR (1) AR053680A1 (de)
AT (1) ATE516044T1 (de)
AU (1) AU2006215761B2 (de)
BR (1) BRPI0608877B8 (de)
CA (1) CA2598290C (de)
CY (1) CY1111916T1 (de)
DK (1) DK1863526T3 (de)
EA (1) EA012046B1 (de)
ES (1) ES2369246T3 (de)
GB (1) GB0503337D0 (de)
HR (1) HRP20110668T1 (de)
IL (1) IL184802A0 (de)
MA (1) MA29321B1 (de)
MX (1) MX2007010075A (de)
MY (1) MY145790A (de)
NO (1) NO341789B1 (de)
NZ (1) NZ560314A (de)
PE (1) PE20061094A1 (de)
PL (1) PL1863526T3 (de)
PT (1) PT1863526E (de)
SI (1) SI1863526T1 (de)
TW (1) TWI358303B (de)
UA (1) UA91044C2 (de)
UY (1) UY29377A1 (de)
WO (1) WO2006087205A1 (de)
ZA (1) ZA200706668B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008014391A (es) * 2006-05-12 2009-03-06 Bharat Biotech Int Ltd Una composicion util como vacuna.
WO2009042202A2 (en) 2007-09-25 2009-04-02 Aridis Pharmaceuticals Formulations for preservation of rota virus
EP2236617A1 (de) 2009-03-31 2010-10-06 Leukocare Ag Verfahren zur Endsterilisierung von biofunktionalen Zusammensetzungen
CN102695522B (zh) 2009-05-12 2016-10-19 美国政府(由卫生和人类服务部、疾病控制和预防中心的部长所代表) 新的人轮状病毒株和疫苗
CN101972475B (zh) * 2010-04-12 2014-04-09 李建平 一种细菌多糖-蛋白结合疫苗及其制备方法
CN101863966B (zh) * 2010-05-21 2012-10-03 中国人民解放军第三军医大学 抗轮状病毒药物作用靶标及其构建方法和应用方法
MX350541B (es) 2010-09-24 2017-09-08 Univ Florida Materiales y metodos para mejorar la funcion gastrointestinal.
EP2471554A1 (de) * 2010-12-28 2012-07-04 Hexal AG Pharmazeutische Formulierung mit biopharmazeutischem Arzneimittel
WO2012103464A2 (en) * 2011-01-28 2012-08-02 Brian Pulliam Oral thin film vaccine preparation
BR112013027457A2 (pt) * 2011-04-28 2019-09-24 Int Medica Foundation preparação de vacina, e, métodos de fabricar uma preparação de vacina, e de vacinar um mamífero
CN102349932B (zh) * 2011-10-12 2012-12-26 刘壮华 一种治疗息肉的药物制剂
WO2013105105A2 (en) * 2012-01-13 2013-07-18 Serum Institute Of India Ltd. Novel viral vaccine compositions and methods for preparing such vaccines
HK1204290A1 (en) * 2012-02-08 2015-11-13 University Of Florida Research Foundation, Inc. Materials and methods for treating diarrhea
WO2013133702A1 (en) * 2012-03-05 2013-09-12 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Methods and compositions for stabilizing dried biological materials
CN110227152A (zh) * 2012-04-23 2019-09-13 巴拉特生物技术国际有限公司 轮状病毒疫苗组合物及其制备方法
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
EP2968241B1 (de) 2013-03-11 2018-10-31 University of Florida Research Foundation, Inc. Materialien und verfahren zur verbesserung der lungenfunktion und zur vorbeugung und/oder behandlung von strahlungsinduzierten lungenkomplikationen
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
US9480739B2 (en) * 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
CN103316335B (zh) * 2013-05-31 2014-11-12 北京科兴生物制品有限公司 一种适于口服的脊髓灰质炎病毒疫苗
CN103316336B (zh) * 2013-05-31 2015-01-28 北京科兴中维生物技术有限公司 一种适于口服的轮状病毒疫苗
WO2015007912A1 (en) * 2013-07-19 2015-01-22 Hexal Ag Methods and formulations which allow the modulation of immune responses related to the administration of a biopharmaceutical drug
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
JP2015091791A (ja) * 2013-10-03 2015-05-14 日東電工株式会社 インフルエンザワクチン乾燥製剤、及び、インフルエンザワクチン乾燥製剤の製造方法
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
CN113730564A (zh) * 2014-12-08 2021-12-03 武汉生物制品研究所有限责任公司 口服六价重配轮状病毒活疫苗
EP3359651A1 (de) 2015-10-05 2018-08-15 THE UNITED STATES OF AMERICA, represented by the S Stamm des menschlichen rota-virus g9p[6] und verwendung als impfstoff
MX2018007413A (es) 2015-12-18 2018-08-15 Merck Sharp & Dohme Formulaciones de vacuna contra rotavirus termicamente estable y metodos de uso de la misma.
MA44557B1 (fr) 2016-06-16 2021-11-30 Bharat Biotech Int Ltd Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer
GB201614799D0 (en) * 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
US20210379186A1 (en) * 2018-04-16 2021-12-09 Merck Patent Gmbh Additives for protein formulations to improve thermal stability
CN110946871A (zh) * 2019-12-12 2020-04-03 浙江华康药业股份有限公司 槐糖在制备预防和治疗肥胖产品中的应用及对应产品
CN115531364B (zh) * 2021-06-30 2024-02-23 中国科学技术大学 预防或治疗轮状病毒感染的微生物代谢物制剂及其用途
CN113994925B (zh) * 2021-12-30 2022-04-26 北京赛尔富森生物科技有限公司 一种轮状病毒攻毒动物模型及其建立方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2505657A1 (fr) 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
JP2849632B2 (ja) 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
KR0171434B1 (ko) * 1990-11-16 1999-02-01 윌리엄 케이. 슈버트 인체 로타바이러스, 백신 및 방법
NZ240818A (en) * 1990-12-14 1993-08-26 Mcneil Ppc Inc Liquid sucralose concentrate compositions containing preservative, buffer and liquid
EP0598037A1 (de) * 1991-08-05 1994-05-25 Sanofi Gepufferte peg-sod zusammensetzungen
JP3723231B2 (ja) 1991-12-23 2005-12-07 ディミナコ アクチェンゲゼルシャフト アジュバント
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
PL181241B1 (pl) 1993-11-17 2001-06-29 Deutsche Om Arzneimittel Gmbh Disacharydy beta(1 6)glukozoaminowe, sposób wytwarzania disacharydu beta(1 6) glukozoaminowego, zawierająca je kompozycja farmaceutyczna i środek immunomodulujący i/lub przeciwnowotworowy oraz szczepionka
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6019982A (en) 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6403098B1 (en) * 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
US6616931B1 (en) * 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
WO1998013065A1 (en) 1996-09-26 1998-04-02 Merck & Co., Inc. Rotavirus vaccine formulations
US5932223A (en) * 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
CN1326564C (zh) 1997-04-01 2007-07-18 科里克萨有限公司 单磷酰基脂质a的水性免疫佐剂组合物
WO1998056415A1 (en) 1997-06-11 1998-12-17 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
GB9725084D0 (en) * 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
US6919076B1 (en) * 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
AU7924598A (en) 1998-06-08 1999-12-30 Sca Emballage France Fast flattening packaging
CN1168702C (zh) 1998-06-30 2004-09-29 Om药业 酰基-二肽类化合物,其制备方法以及含有前述化合物的药物组合物
TR200200420T2 (tr) * 1999-08-17 2002-05-21 Smithkline Beecham Biologicals S.A. Aşı
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
EP1251869B1 (de) * 2000-01-28 2010-03-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES Immunogenischen zusammensetzung von lebendigen rotaviren mit verringertem risiko von nebenwirkungen

Also Published As

Publication number Publication date
CA2598290A1 (en) 2006-08-24
CN101300028A (zh) 2008-11-05
EP2322211A1 (de) 2011-05-18
AU2006215761B2 (en) 2011-03-17
KR20070103506A (ko) 2007-10-23
CN103357005A (zh) 2013-10-23
US20080166372A1 (en) 2008-07-10
HRP20110668T1 (hr) 2011-10-31
PT1863526E (pt) 2011-10-11
BRPI0608877B1 (pt) 2021-02-09
TW200640486A (en) 2006-12-01
CA2598290C (en) 2015-08-11
MX2007010075A (es) 2008-01-16
NO20073868L (no) 2007-11-15
US8821891B2 (en) 2014-09-02
AU2006215761A1 (en) 2006-08-24
PL1863526T3 (pl) 2011-12-30
AR053680A1 (es) 2007-05-16
CY1111916T1 (el) 2015-11-04
EA200701519A1 (ru) 2008-02-28
ES2369246T3 (es) 2011-11-28
DK1863526T3 (da) 2011-10-24
US8192747B2 (en) 2012-06-05
BRPI0608877B8 (pt) 2021-05-25
EA012046B1 (ru) 2009-08-28
KR101319846B1 (ko) 2013-10-22
BRPI0608877A2 (pt) 2012-07-31
MA29321B1 (fr) 2008-03-03
ZA200706668B (en) 2009-07-29
NZ560314A (en) 2011-02-25
CN101300028B (zh) 2014-06-04
JP2008530165A (ja) 2008-08-07
GB0503337D0 (en) 2005-03-23
MY145790A (en) 2012-04-30
SI1863526T1 (sl) 2011-11-30
US20120237547A1 (en) 2012-09-20
PE20061094A1 (es) 2006-11-30
AP2007004087A0 (en) 2007-08-31
JP5118977B2 (ja) 2013-01-16
AP2692A (en) 2013-07-16
WO2006087205A1 (en) 2006-08-24
EP1863526B1 (de) 2011-07-13
IL184802A0 (en) 2007-12-03
NO341789B1 (no) 2018-01-22
UY29377A1 (es) 2006-10-02
TWI358303B (en) 2012-02-21
UA91044C2 (uk) 2010-06-25
EP1863526A1 (de) 2007-12-12

Similar Documents

Publication Publication Date Title
ATE516044T1 (de) Attenuierte rotavirus-vakzine zur oralen verabreichung
HUS2200002I1 (hu) Immunogén készítmény
HUE062920T2 (hu) Eljárások vakcina beadására
ATE462445T1 (de) Prrs-impfstoffe
ATE450271T1 (de) Impfstoff
EP1885415A4 (de) Vorrichtung zur medikamentverabreichung
DK1959991T3 (da) Terapeutisk vaccine
DK1968631T3 (da) Vaccine
ATE516817T1 (de) Impfstoffe zur immunisierung gegen helicobacter
DK2066354T3 (da) Norovirus vaccine formuleringer
EP1992348A4 (de) Pharmazeutische kombination
MA28609B1 (fr) Vaccins
ZA200709835B (en) Oral dosage form comprising an antimisuse system
MA28885B1 (fr) vaccins
EP2133092A4 (de) Oraler impfstoff
MA28639B1 (fr) Vaccins
EP2061502A4 (de) Kohlenhydrat-basierte impfstoffe für hlv
NO20100811A (no) Subenhetsvaksine for akvakutur
EP2016414A4 (de) T-zell vakzin
EP1872794A4 (de) Nasale vakzine
AP2695A (en) Vaccine adjuvants
HK1115541A (en) Live attenuated rotavirus vaccine for oral administration
EP1745780A4 (de) Medizinisches präparat
FI20060582A0 (fi) Farmaseuttinen valmiste
EP2136835A4 (de) Impstoff

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1863526

Country of ref document: EP